March is here, and as we observe Kidney Month, it’s crucial to raise awareness about how lupus can severely impact the ...

In a new study, researchers investigated microRNA-203 as a potential biomarker for lupus nephritis (LN) and found that ...

USA: Researchers have found in a new study that kidney function during the second trimester plays a crucial role in ...

Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront.

LN的流行病学特征复杂多样，受种族、地域、社会经济等多种因素影响；其发病机制涉及遗传、环境（包括紫外线、空气污染、病毒感染、肠道菌群与食物因素）、免疫等多个方面，是多种因素相互作用的结果。深入研究这些方面，有助于开发更精准的诊断方法和更有效的治疗策略 ...

During the year ended December 31, 2024, net cash used in operating activities was $134.7 million, compared to $92.2 million ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...

Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...

The following is a summary of “Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis,” published in the February 2025 ...